APOC3 RNAi Agents for Hepatocyte-Targeted Triglyceride Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertriglyceridemia and related cardiovascular diseases are often ineffective, especially in severe cases, and there is a need for a therapeutic that can substantially lower triglyceride and cholesterol levels by selectively inhibiting apolipoprotein C-III (APOC3) gene expression.
Innovation Solution
Development of APOC3-specific RNA interference (RNAi) agents that are designed to selectively and efficiently inhibit APOC3 gene expression, using double-stranded RNAi agents conjugated to targeting ligands like N-acetyl-galactosamine to facilitate delivery to liver cells, particularly hepatocytes, thereby reducing TG and cholesterol levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (fibrates or statins) are used for hypertriglyceridemia, then treatment is provided for moderate cases, but the reduction in serum TG is modest and ineffective in severe cases
Solution Approach 1:
The patent extracts and targets the specific gene (APOC3) responsible for triglyceride metabolism dysfunction. By designing RNAi agents that specifically bind to APOC3 mRNA, the treatment isolates the pathological target from the complex lipid metabolism system, enabling selective inhibition of the problematic apolipoprotein while preserving other metabolic functions.
Solution Approach 2:
The patent changes the therapeutic approach from modulating lipid levels indirectly (via fibrates/statins) to directly suppressing APOC3 gene expression. This parameter change from indirect metabolic modulation to direct gene silencing achieves substantially greater TG reduction, particularly in severe hypertriglyceridemia cases where conventional therapies fail.
2Reliability
If APOC3-specific RNAi agents are developed to substantially lower TG levels, then therapeutic effectiveness is improved, but delivery to liver cells must be optimized
Solution Approach 1:
The patent introduces targeting ligands as intermediary molecules that bridge the RNAi agent and the liver cell surface receptors. These ligands specifically bind to receptors on hepatocytes, mediating the delivery of the therapeutic RNAi agent to the intended target cells while protecting it from degradation and ensuring efficient cellular uptake.
Solution Approach 2:
The patent segments the therapeutic system into distinct functional components: the RNAi agent (for gene silencing), the targeting ligand (for cell-specific delivery), and the conjugation linkage (for stable attachment). This segmentation allows each component to be optimized independently for its specific function while maintaining overall system effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The APOC3 RNAi agents effectively reduce TG and cholesterol levels, providing therapeutic benefits for conditions such as hypertriglyceridemia, cardiovascular disease, and other metabolic disorders by inhibiting APOC3 gene expression.
Implementation Method 1
APOC3 RNAi agents for inhibiting expression of apolipoprotein C-III (APOC3)... double-stranded RNAi agents conjugated to targeting ligands like N-acetyl-galactosamine to facilitate delivery to liver cells, particularly hepatocytes
Implementation Method 2
RNA interference (RNAi) agents, e.g., double stranded RNAi agents, for inhibition of apolipoprotein C-III gene expression... APOC3-specific RNA interference (RNAi) agents that are designed to selectively and efficiently inhibit APOC3 gene expression
Data Source
AI summary
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.